Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT04519151Phase 2Recruiting
- Sponsor
- Sheba Medical Center
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in ovarian cancer, sponsored by Sheba Medical Center. Started Apr 2021; status: recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04519151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519151.